Comparative Pharmacology
Head-to-head clinical analysis: PEDIAMYCIN 400 versus WYAMYCIN S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEDIAMYCIN 400 versus WYAMYCIN S.
PEDIAMYCIN 400 vs WYAMYCIN S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
WYAMYCIN S (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
400 mg orally every 6 hours for 10 days.
WYAMYCIN S (clarithromycin/sulfamethoxazole) is a fixed-dose combination. Adult: 1 tablet (500 mg clarithromycin/800 mg sulfamethoxazole) orally every 12 hours for 7-14 days.
None Documented
None Documented
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
2-3 hours in normal renal function; prolonged to 24-48 hours in end-stage renal disease.
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Renal (90-95% unchanged via glomerular filtration) and biliary (<5%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic